Glaucoma Research Foundation: Advancing Vision & Hope
Glaucoma Articles
This is the place for the latest information about our work here at Glaucoma Research Foundation and for current events in the world of eye health. All breakthroughs and insights are made possible through the dedication of researchers, and through the continued financial support and active involvement of the community.
Easier Glaucoma Diagnosis with Smartphone Apps and Artificial Intelligence
Researchers are working on some amazing things that artificial intelligence (AI) can do for glaucoma sufferers, especially in the areas of diagnosis and disease management, but it will take time and more work.
New Gel Stent Device Could Be A Better Surgical Option for Glaucoma Patients
There are new treatment options on the horizon that may help reduce the number of traditional surgeries while increasing effectiveness.
Discovering Matrix Metalloproteinases and How They Could Lead to Future Glaucoma Treatments
Matrix metalloproteinases (or MMPs) may sound like something out of a sci-fi story, but they’re a real-life family of enzymes—the metzincin superfamily—that thrive inside the human body.
Restoring Peripheral Vision to Glaucoma Patients with Prism Glasses
Researchers are developing a new type of glasses that contain a prism that will redirect the sight of a person with limited peripheral vision.
Optic Nerve Regeneration
Glaucoma causes damage to the optic nerve, which can result in an eventual loss of vision.
Dr. Andrew Huberman: What Motivates Me as a Scientist
“What motivates me is the very real possibility of discovering something in my laboratory that can allow patients to see to see much better, for much longer periods of their life, and maybe even reverse blindness.”
Research On Retinal Pigment Epithelial (RPE) Cells Promises New Future Treatment for Glaucoma Patients
Glaucoma doesn’t typically damage RPE cells, but thanks to advances in stem cell research, it looks like RPE cells may play a crucial role in finding a cure to the degenerative disease.
Unique Mapping Device Upgrades Glaucoma Eye Exam to Enhance Individualized Treatment
Optical coherence tomography (OCT) scans offer better diagnostic accuracy by letting doctors see changes inside the eye.
Powerful, Transformative Research: An Interview with Shaffer Prize Winner Dr. Richard Libby
We are honored to introduce you to a prominent researcher whose work in glaucoma may one day lead to a cure: Dr. Richard Libby.
A Timeline for Glaucoma Therapy Development: Reality and Risks Of Pharmaceutical Research
No one can predict the next big breakthrough in glaucoma treatment, but one thing is certain: A whole lot of experts are searching for ways to make the future better.
GRF Scientific Advisors discuss the Importance of Biomarkers for Glaucoma
Catalyst for a Cure (CFC) is a collaborative team of investigators funded by Glaucoma Research Foundation.
Occupational Therapy Training Helps Low Vision Patients
In an attempt to demonstrate that low vision patients have good potential for overcoming vision loss, researchers undertook a study and presented their findings.
Working Together to Find Biomarkers for Glaucoma Means Lower Risk of Vision Loss
With exciting new biomarkers on the horizon, this is a good time to learn more about what they are and how they’ll ultimately help find a cure for glaucoma.
Promising New Procedure Targets Vascular Changes to Diagnose Glaucoma Early
While this is a major breakthrough, OCT angiography must be improved before it will be ready for use in your doctor’s office.
Could Cataract Surgery Be A New Treatment Option for Primary Closed-Angle Glaucoma?
Data published in October 2016 shows there is a successful, safe, routine surgical procedure that has been restoring eyesight for ages, and it may be the answer to treating primary closed-angle glaucoma (PCAG).
Innovations in Microinvasive Techniques May Inspire New Pediatric Glaucoma Treatments
We need new and better treatments for pediatric glaucoma. Progress in micro-invasive techniques aimed at adults with glaucoma gives researchers reason to hope.
Glaucoma Biomarkers: from the Laboratory to the Clinic
Catalyst for a Cure researchers have been taking necessary steps to move their studies from the laboratory to the clinic.
New Nitric Oxide Medication to Reduce Intraocular Pressure Takes on Glaucoma from a New Angle
Nitric oxide has become a popular dietary supplement because it can help improve blood flow and lower blood pressure. As it turns out, nitric oxide also works as a glaucoma treatment.
Science Fiction May Hint at Vision-Restoring Prostheses for Glaucoma Patients
Researchers are developing and validating new technologies that could enable less invasive approaches for vision prosthetics.
Newly Funded Research Promoting Retinal Cell Axon Regeneration is Underway Thanks to NEI’s Audacious Goals Initiative
Optic nerve regeneration could be the answer to curing glaucoma, or at least substantially slowing the progression of the disease.
Danielle Fiarito: A Story of Hope and Inspiration
When Glaucoma Research Foundation (GRF) first learned of Danielle Fiarito, she was a teenager coping bravely with her disease.
Why Induced Pluripotent Stem Cells Are Vital for Glaucoma Research and Treatments
Stem cells are poised to make an impact on glaucoma research and treatment, as adult stem cells can be taken from the eye or skin, and used to try to replace damaged cells in your eye.
Frank Stein and Paul S. May: Devoted to Helping Families Thrive, Supporting People with Low Vision and Finding a Cure for Glaucoma
Frank and Paul strongly believe that research will ultimately lead to a cure for glaucoma.
Allergan Receives FDA Approval for XEN Glaucoma Treatment System
On November 22, 2016, Allergan announced that the U.S. Food and Drug Administration (FDA) has cleared the XEN® Glaucoma Treatment System for use in the United States.
New Contact Lens Technology Could Change the Lives of Glaucoma Patients
New contact lens technologies could make it easier for patients to comply with their medication plans and monitor both the progress of the disease and the efficacy of newly prescribed drugs.